ROMA RISK OF OVARIAN MALIGNANCY ALGORITHM: A Complete Guide
Women’s reproductive health involves several areas of care, and ovarian health is an important part of it. When an ovarian or adnexal mass is identified during a clinical examination or imaging study, doctors may need additional information to understand whether the mass is more likely to be benign or associated with malignancy.
ROMA RISK OF OVARIAN MALIGNANCY ALGORITHM is a laboratory-based risk assessment that combines specific blood-test results with menopausal status to help classify the likelihood of malignancy in women who have an ovarian adnexal mass.
The ROMA approach uses HE4 and CA-125 measurements together with menopausal status to generate a numerical risk score. Importantly, ROMA is not intended to be used as a general screening test for ovarian cancer or as a standalone diagnostic test. It should be interpreted along with clinical assessment and appropriate imaging.
At areyouhealthy.in, we offer health checkup and diagnostic packages for customers across India. We are a channel partner of ThyroCare, helping customers access laboratory testing through a convenient diagnostic network.
For women in Delhi NCR, Mumbai, Bengaluru, Hyderabad, Chennai, Pune, Kolkata, Ahmedabad, Jaipur, Surat, Lucknow, Kanpur, Nagpur, and Indore, accessible diagnostic services can make it easier to complete recommended laboratory investigations.
What Is ROMA RISK OF OVARIAN MALIGNANCY ALGORITHM?
ROMA stands for Risk of Ovarian Malignancy Algorithm.
ROMA RISK OF OVARIAN MALIGNANCY ALGORITHM combines:
- HE4, or human epididymis protein 4
- CA-125, or cancer antigen 125
- Menopausal status
These inputs are used to calculate a numerical score that categorises a woman with an ovarian adnexal mass into a higher- or lower-likelihood group for malignancy.
The test is intended for women over 18 who have an ovarian adnexal mass for which surgery is planned, under the specific intended-use conditions described for the test. It is not intended to determine whether surgery should take place by itself.
Why Is ROMA Testing Used?
An ovarian or adnexal mass can have many possible causes. Many masses are benign, while others may require more extensive evaluation.
When a mass has already been identified, doctors may use multiple pieces of information to assess the situation. These may include:
- Symptoms
- Physical examination
- Ultrasound findings
- Other imaging
- Menopausal status
- CA-125
- HE4
- ROMA score
- Medical and reproductive history
ROMA can provide additional information within this broader assessment.
The purpose is not to replace clinical judgment but to help support risk stratification and decisions about appropriate specialist management.
Understanding HE4
HE4 is a protein that can be measured in blood.
It is one of the biomarkers incorporated into the ROMA calculation. HE4 may be elevated in some epithelial ovarian cancers, but its interpretation depends on the clinical setting.
HE4 should not be treated as a standalone ovarian-cancer screening test. Mayo Clinic Laboratories specifically notes that HE4 should not be used as a screening test for ovarian cancer.
HE4 can also be influenced by factors other than ovarian malignancy, which is why the result needs to be interpreted in context.
Understanding CA-125
CA-125 is another blood marker commonly associated with ovarian-related evaluation.
Although CA-125 can be elevated in ovarian cancer, it can also increase in several benign conditions and other medical situations.
Therefore, an elevated CA-125 result does not automatically mean that a woman has ovarian cancer.
Similarly, a normal CA-125 result does not independently rule out ovarian malignancy.
This is one reason ROMA combines CA-125 with HE4 and menopausal status rather than relying on CA-125 alone.
Role of Menopausal Status
Menopausal status is an important component of the ROMA calculation.
The interpretation of the score differs between premenopausal and postmenopausal women because the relevant clinical thresholds are different.
For the FDA-cleared ROMA system described in the referenced documentation, the reported clinical cutoffs are:
| Menopausal status | ROMA interpretation |
|---|---|
| Premenopausal | Score below 1.31: low likelihood; 1.31 or higher: high likelihood |
| Postmenopausal | Score below 2.77: low likelihood; 2.77 or higher: high likelihood |
These cutoffs apply to the specific validated ROMA system and intended-use population and should not automatically be applied to every laboratory’s assay or methodology.
Who May Be Considered for ROMA Testing?
ROMA RISK OF OVARIAN MALIGNANCY ALGORITHM may be considered when a healthcare professional has identified an ovarian adnexal mass and believes that risk assessment could provide useful additional information.
It may be relevant when:
- An ovarian or adnexal mass has been identified
- Imaging requires further clinical risk assessment
- Surgery is being considered
- A doctor is evaluating the likelihood of malignancy
- Additional information is needed alongside clinical and radiological findings
It is not appropriate to use ROMA simply as a general health screening test for women who do not have an identified adnexal mass.
What Is an Adnexal Mass?
The term adnexal mass generally refers to a mass or abnormal growth located in the structures adjacent to the uterus, including the ovaries and fallopian tubes.
An adnexal mass does not automatically mean cancer.
Many ovarian cysts and other adnexal masses are benign.
Doctors may use ultrasound or other imaging techniques to assess characteristics such as:
- Size
- Shape
- Internal structure
- Solid or cystic components
- Blood flow
- Other imaging features
ROMA may provide additional laboratory information when used within the appropriate clinical setting.
Benefits of ROMA RISK OF OVARIAN MALIGNANCY ALGORITHM
1. Supports Risk Stratification
ROMA can help classify women with an adnexal mass into a higher- or lower-likelihood group for malignancy.
2. Combines Multiple Inputs
The algorithm combines HE4, CA-125, and menopausal status rather than relying on a single laboratory marker.
3. Complements Clinical Assessment
ROMA can provide additional information alongside clinical and radiological evaluation.
4. Helps Inform Specialist Referral
When appropriately used, risk assessment can support decisions about whether a patient may benefit from evaluation by a gynaecologic oncology team.
5. Provides a Structured Numerical Result
The algorithm converts the relevant laboratory measurements and menopausal status into a numerical score that can be interpreted according to the validated assay’s thresholds.
ROMA Is Not a Standalone Cancer Diagnosis
This is one of the most important points about ROMA testing.
A high ROMA result does not mean that a woman definitely has ovarian cancer.
A low ROMA result does not guarantee that an ovarian mass is benign.
The FDA states that ROMA should be interpreted alongside independent clinical and radiological assessment and is not intended as a screening or standalone diagnostic assay.
This distinction is important because an ovarian mass requires an overall assessment rather than reliance on a single score.
How Is ROMA Testing Performed?
ROMA is based on a blood sample.
The laboratory measures the relevant biomarkers, such as HE4 and CA-125, and uses menopausal status as part of the algorithm.
The general process through areyouhealthy.in may include:
- Select the relevant ROMA diagnostic service.
- Review the current test details.
- Check preparation requirements.
- Enter the required patient information.
- Arrange the available sample collection option.
- Provide the blood sample.
- The laboratory processes the specimen.
- Receive the report.
- Discuss the findings with your gynaecologist or treating doctor.
Sample collection availability and reporting timelines can vary according to location and service availability.
Is Fasting Required for ROMA Testing?
Preparation requirements can depend on the laboratory and the tests being performed.
ROMA is based on serum biomarkers, but customers should follow the specific preparation instructions provided for their booked test.
If additional laboratory investigations are being performed at the same time, fasting may be required because of those additional tests.
Always follow the instructions provided by the laboratory or healthcare professional.
Understanding Your ROMA Report
ROMA results should be interpreted according to the specific assay and laboratory methodology used.
The report may provide:
- HE4 result
- CA-125 result
- Menopausal classification
- ROMA score
- Risk category
The interpretation should be performed by the treating healthcare professional.
Your doctor may also consider:
- Ultrasound findings
- Symptoms
- Age
- Menopausal status
- Medical history
- Family history
- Previous reports
- Physical examination
- Other laboratory investigations
ROMA RISK OF OVARIAN MALIGNANCY ALGORITHM for Indian Women
Women across India may undergo evaluation for ovarian or adnexal masses.
Customers in Delhi NCR, Mumbai, Bengaluru, Hyderabad, Chennai, and Pune may seek convenient access to laboratory testing alongside consultations and imaging.
Women in Kolkata, Ahmedabad, Jaipur, Surat, Lucknow, Kanpur, Nagpur, and Indore may similarly require diagnostic services when an ovarian mass is identified.
ROMA RISK OF OVARIAN MALIGNANCY ALGORITHM can be considered when the test is clinically appropriate and its intended-use criteria are met.
It should not be marketed or understood as a routine ovarian-cancer screening test.
When Should You Consult a Gynaecologist?
Women should consult a qualified healthcare professional when an ovarian or adnexal mass has been identified or when they experience persistent concerning symptoms.
Potential symptoms that warrant medical evaluation can include:
- Persistent pelvic discomfort
- Abdominal swelling or bloating
- Pelvic pain
- Changes in urinary habits
- Changes in bowel habits
- Unexplained weight changes
- Abnormal vaginal bleeding
- Persistent abdominal symptoms
These symptoms can have many possible causes and do not automatically indicate ovarian cancer.
Why Choose AreYouHealthy.in?
At areyouhealthy.in, we aim to make diagnostic testing accessible and convenient for customers across India.
We offer health checkup and diagnostic packages designed for different healthcare requirements. We are a channel partner of ThyroCare, helping customers access laboratory testing through an established diagnostic network.
Customers can explore our health checkup packages for additional diagnostic options.
Women looking for broader preventive screening can explore our women’s health checkup options.
For fertility and reproductive-health concerns, customers can also explore our infertility profile options.
Frequently Asked Questions About ROMA RISK OF OVARIAN MALIGNANCY ALGORITHM
1. What is ROMA RISK OF OVARIAN MALIGNANCY ALGORITHM?
ROMA RISK OF OVARIAN MALIGNANCY ALGORITHM is a laboratory-based risk assessment that combines HE4, CA-125, and menopausal status to classify the likelihood of malignancy in women with an ovarian adnexal mass.
2. Is ROMA a test for ovarian cancer screening?
No. ROMA is not intended as a general screening test for ovarian cancer. It is intended for specific clinical situations involving an ovarian adnexal mass and should be interpreted with clinical and imaging findings.
3. What does ROMA stand for?
ROMA stands for Risk of Ovarian Malignancy Algorithm.
4. Which biomarkers are used in ROMA?
The ROMA approach uses HE4 and CA-125 along with menopausal status to calculate the score.
5. Does a high ROMA score mean I have ovarian cancer?
No. A high-risk ROMA result does not by itself diagnose ovarian cancer. It indicates a higher likelihood category within the intended clinical setting and must be interpreted with other clinical and radiological information.
6. Does a low ROMA score rule out ovarian cancer?
No. A low-risk result does not guarantee that an adnexal mass is benign. Clinical and imaging assessment remain important.
7. Why is menopausal status important in ROMA?
The ROMA calculation and clinical thresholds differ between premenopausal and postmenopausal women. The validated assay uses menopausal status as part of the risk calculation.
8. What are the ROMA cutoffs?
For the specific FDA-cleared ROMA system described in its documentation, a score of 1.31 or higher is classified as high likelihood in premenopausal women, while 2.77 or higher is classified as high likelihood in postmenopausal women. Laboratory-specific methodology and reporting should always be followed.
9. Does ROMA replace an ultrasound?
No. ROMA is intended to be used alongside independent clinical and radiological assessment.
10. Can an ovarian cyst cause a high ROMA score?
ROMA is intended to help risk-stratify women with an adnexal mass, but the score cannot by itself establish whether a mass is cancerous or benign. A doctor should interpret the result alongside imaging and clinical findings.
11. Can CA-125 alone diagnose ovarian cancer?
No. CA-125 can be elevated for several reasons, including some benign conditions. It should not be used alone to diagnose ovarian cancer.
12. What is HE4?
HE4 is a blood biomarker incorporated into the ROMA calculation. It can be elevated in some ovarian cancers, but it is not intended as a standalone screening test.
13. Is ROMA testing suitable for every woman?
No. ROMA is intended for specific clinical circumstances, particularly women with an ovarian adnexal mass under the test’s intended-use criteria. It is not a general health screening test for all women.
14. Should I take ROMA testing without consulting a doctor?
It is preferable to discuss the test with your gynaecologist or treating healthcare professional, particularly because ROMA is designed for use alongside clinical and radiological evaluation.
15. What should I do if my ROMA result is high?
Do not panic or interpret the result as a cancer diagnosis. Discuss the report promptly with your gynaecologist or treating doctor, who can interpret the result alongside imaging, symptoms, medical history, and other relevant findings.
Understanding Ovarian Health Through Appropriate Evaluation
An ovarian or adnexal mass can be concerning, but many such masses are benign. Appropriate evaluation combines clinical assessment, imaging, laboratory information, and medical history.
ROMA RISK OF OVARIAN MALIGNANCY ALGORITHM can provide additional risk-stratification information in the appropriate clinical setting by combining HE4, CA-125, and menopausal status. It should not be used as a standalone diagnostic test or as a general screening test for ovarian cancer.
At areyouhealthy.in, customers across India can explore diagnostic and health checkup services supported by our ThyroCare channel partnership.
If an ovarian or adnexal mass has been identified, discuss the appropriate diagnostic pathway with your gynaecologist. Depending on the individual situation, this may involve ultrasound, laboratory testing, specialist consultation, monitoring, or other investigations.
Before booking ROMA RISK OF OVARIAN MALIGNANCY ALGORITHM, confirm the current test methodology, sample requirements, preparation instructions, and reporting details. Most importantly, use the result as part of a complete medical evaluation rather than interpreting the ROMA score on its own.